Royalty Pharma plc Earnings Per Share (Basic)
Royalty Pharma plc (RPRX) reported Earnings Per Share (Basic) of $0.04 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- Royalty Pharma plc earnings per share, basic for the quarter ending 2026-06-30 was $0.04, a 50.00% decline year-over-year.
- Royalty Pharma plc earnings per share, basic for the quarter ending 2026-03-31 was $0.67, a 21.82% increase year-over-year.
- Royalty Pharma plc earnings per share, basic for the quarter ending 2025-12-31 was $0.50, a 6.99% increase year-over-year.
- Royalty Pharma plc earnings per share, basic for the quarter ending 2025-09-30 was $0.67, a 45.08% decline year-over-year.
- Royalty Pharma plc earnings per share, basic for fiscal 2025 was $1.79, a 6.77% decline from fiscal 2024.
- Royalty Pharma plc earnings per share, basic for fiscal 2024 was $1.92, a 24.41% decline from fiscal 2023.
- Royalty Pharma plc earnings per share, basic for fiscal 2023 was $2.54, a 2440.00% increase from fiscal 2022.
- Royalty Pharma plc earnings per share, basic for fiscal 2022 was $0.10, a 93.29% decline from fiscal 2021.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.04 10-Q · filed 2026-08-05 | $0.71 10-Q · filed 2026-08-05 | $1.21 derived: net income ÷ weighted average shares · filed 2026-08-05 | $1.87 derived: net income ÷ weighted average shares · filed 2026-08-05 | |
| 2026-03-31 | $0.67 10-Q · filed 2026-05-06 | $1.18 derived: net income ÷ weighted average shares · filed 2026-05-06 | $1.84 derived: net income ÷ weighted average shares · filed 2026-05-06 | $1.93 derived: net income ÷ weighted average shares · filed 2026-08-05 | |
| 2025-12-31 | $0.50 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.17 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.25 derived: net income ÷ weighted average shares · filed 2026-08-05 | $1.79 10-K · filed 2026-02-11 | |
| 2025-09-30 | $0.67 10-Q · filed 2025-11-05 | $0.75 derived: net income ÷ weighted average shares · filed 2026-08-05 | $1.29 10-Q · filed 2025-11-05 | $1.77 derived: net income ÷ weighted average shares · filed 2026-08-05 | |
| 2025-06-30 | $0.08 10-Q · filed 2026-08-05 | $0.07 10-Q · filed 2025-08-06 | $0.63 10-Q · filed 2026-08-05 | $1.10 derived: net income ÷ weighted average shares · filed 2026-08-05 | $2.34 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | $0.55 10-Q · filed 2026-05-06 | $1.02 derived: net income ÷ weighted average shares · filed 2026-05-06 | $2.24 derived: net income ÷ weighted average shares · filed 2026-05-06 | $2.46 derived: net income ÷ weighted average shares · filed 2026-05-06 | |
| 2024-12-31 | $0.47 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.68 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.91 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.92 10-K · filed 2026-02-11 | |
| 2024-09-30 | $1.22 10-Q · filed 2025-11-05 | $1.44 derived: net income ÷ weighted average shares · filed 2025-11-05 | $1.45 10-Q · filed 2025-11-05 | $2.55 derived: net income ÷ weighted average shares · filed 2026-02-11 | |
| 2024-06-30 | $0.23 10-Q · filed 2025-08-06 | $0.24 10-Q · filed 2025-08-06 | $1.34 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.50 derived: net income ÷ weighted average shares · filed 2026-02-11 | |
| 2024-03-31 | $0.01 10-Q · filed 2025-05-08 | $1.12 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.28 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.78 derived: net income ÷ weighted average shares · filed 2026-02-11 | |
| 2023-12-31 | $1.11 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.27 derived: net income ÷ weighted average shares · filed 2026-02-11 | $1.77 derived: net income ÷ weighted average shares · filed 2026-02-11 | $2.54 10-K · filed 2026-02-11 | |
| 2023-09-30 | $0.16 10-Q · filed 2024-11-06 | $0.67 derived: net income ÷ weighted average shares · filed 2024-11-06 | $1.43 10-Q · filed 2024-11-06 | $0.41 derived: net income ÷ weighted average shares · filed 2025-02-12 | |
| 2023-06-30 | $0.51 10-Q · filed 2024-08-08 | $1.27 10-Q · filed 2024-08-08 | $0.25 derived: net income ÷ weighted average shares · filed 2025-02-12 | $0.57 derived: net income ÷ weighted average shares · filed 2025-02-12 | |
| 2023-03-31 | $0.76 10-Q · filed 2024-05-09 | -$0.26 derived: net income ÷ weighted average shares · filed 2025-02-12 | $0.06 derived: net income ÷ weighted average shares · filed 2025-02-12 | $0.75 derived: net income ÷ weighted average shares · filed 2025-02-12 | |
| 2022-12-31 | -$1.03 derived: net income ÷ weighted average shares · filed 2025-02-12 | -$0.71 derived: net income ÷ weighted average shares · filed 2025-02-12 | -$0.02 derived: net income ÷ weighted average shares · filed 2025-02-12 | $0.10 10-K · filed 2025-02-12 | |
| 2022-09-30 | $0.32 10-Q · filed 2023-11-08 | $1.02 derived: net income ÷ weighted average shares · filed 2023-11-08 | $1.14 10-Q · filed 2023-11-08 | $1.16 derived: net income ÷ weighted average shares · filed 2024-02-15 | |
| 2022-06-30 | $0.70 10-Q · filed 2023-08-08 | $0.82 10-Q · filed 2023-08-08 | $0.84 derived: net income ÷ weighted average shares · filed 2024-02-15 | $1.08 derived: net income ÷ weighted average shares · filed 2024-02-15 | |
| 2022-03-31 | $0.12 10-Q · filed 2023-05-09 | $0.14 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.37 derived: net income ÷ weighted average shares · filed 2024-02-15 | $1.41 derived: net income ÷ weighted average shares · filed 2024-02-15 | |
| 2021-12-31 | $0.02 derived: net income ÷ weighted average shares · filed 2024-02-15 | $0.26 derived: net income ÷ weighted average shares · filed 2024-02-15 | $1.30 derived: net income ÷ weighted average shares · filed 2024-02-15 | $1.49 10-K · filed 2024-02-15 | |
| 2021-09-30 | $0.24 10-Q · filed 2022-11-08 | $1.30 derived: net income ÷ weighted average shares · filed 2022-11-08 | $1.49 10-Q · filed 2022-11-08 | $1.93 derived: net income ÷ weighted average shares · filed 2023-02-15 | |
| 2021-06-30 | $1.08 10-Q · filed 2022-08-04 | $1.28 10-Q · filed 2022-08-04 | $1.71 derived: net income ÷ weighted average shares · filed 2023-02-15 | $2.48 derived: net income ÷ weighted average shares · filed 2023-02-15 | |
| 2021-03-31 | $0.18 10-Q · filed 2022-05-05 | $0.61 derived: net income ÷ weighted average shares · filed 2023-02-15 | $1.37 derived: net income ÷ weighted average shares · filed 2023-02-15 | $1.49 derived: net income ÷ weighted average shares · filed 2023-02-15 | |
| 2020-12-31 | $0.43 derived: net income ÷ weighted average shares · filed 2023-02-15 | $1.20 derived: net income ÷ weighted average shares · filed 2023-02-15 | $1.32 derived: net income ÷ weighted average shares · filed 2023-02-15 | $1.32 10-K · filed 2023-02-15 | |
| 2020-09-30 | $0.79 10-Q · filed 2021-11-10 | $0.90 derived: net income ÷ weighted average shares · filed 2021-11-10 | $0.88 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $0.09 10-Q · filed 2021-08-11 | $0.09 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |